ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MAR Maravai LifeSciences Holdings Inc

7.05
0.00 (0.00%)
06:32:02 - Realtime Data
Share Name Share Symbol Market Type
Maravai LifeSciences Holdings Inc TG:MAR Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 7.05 6.95 7.10 0.00 06:32:02

Marriott Swings To 3Q Loss On Timeshare Write-Downs

08/10/2009 12:39pm

Dow Jones News


Maravai LifeSciences (TG:MAR)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Maravai LifeSciences Charts.
   DOW JONES NEWSWIRES 
 

Marriott International Inc. (MAR) swung to fiscal-third loss amid write-downs of its timeshare business and sagging revenue at its core hotel business, but results edged expectations.

Still there were signs the hotelier has seen the worst of the declines. For the coming fiscal year Marriott expects worldwide revenue per available room may decline as much as 5%, excluding currency effects, with performance strengthening as the year progresses. International markets are expected to show more strength than in North America.

However, due to the economy, the company again declined to provide its typical earnings guidance.

Major time-share companies such as Marriott, Starwood Hotels & Resorts Worldwide Inc. (HOT) and Wyndham Worldwide Corp. (WYN) have scaled back on development and sales the past year. Marriott recently said it would stop new time-share development and exit the luxury residential segment, which includes condominiums and penthouses atop or adjacent to its hotels.

For the quarter ended Sept. 11, the company reported a loss of $466 million, or $1.31 a share, compared with a prior-year profit of $94 million, or 25 cents a share. Excluding items such as the write-downs, earnings fell to 15 cents from 34 cents. The company in July had forecast 9 cents to 14 cents.

Revenue decreased 17% to $2.47 billion as revenue per available room slumped 22%. Analysts polled by Thomson Reuters most recently expected $2.39 billion.

For the fiscal fourth quarter, the company expects earnings of 20 cents to 23 cents on revpar declines of 13% to 16% in North America and 16% to 18% elsewhere in constant dollars. Analysts projected earnings of 22 cents.

Shares closed Wednesday at $26.95 and didn't trade premarket. The stock is up 40% this past year.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; tess.stynes@dowjones.com

 
 

1 Year Maravai LifeSciences Chart

1 Year Maravai LifeSciences Chart

1 Month Maravai LifeSciences Chart

1 Month Maravai LifeSciences Chart

Your Recent History

Delayed Upgrade Clock